Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Low Dose Temozolomide Plus Metformin as Combination Chemotherapy Compared With Low Dose Temozolomide Plus Placebo in Patient With Recurrent or Refractory Glioblastoma

NCT03243851 is registered in ClinicalTrials.gov with Yong-Kil Hong as lead sponsor.

NCT NCT03243851
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03243851 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Low Dose Temozolomide Plus Metformin as Combination Chemotherapy Compared With Low Dose Temozolomide Plus Placebo in Patient With Recurrent or Refractory Glioblastoma
Lead sponsor
Yong-Kil Hong
Phase
Phase 2
Overall status
Completed
Start date
November 21, 2016
Completion date
December 31, 2020
Enrollment
81 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma